Leukemia & Lymphoma Society: Pacific Northwest Region’s Post

The #BloodCancer landscape continues to evolve through scientific innovations that not only clinically benefit patients, but also strengthen their care and quality of life.     Explore the emerging themes this year to watch for with The Leukemia & Lymphoma Society: https://e.lilly/3P0Rm3F  

🌟 Leukemia and Lymphoma Awareness Month: We're Here to Help You Navigate Cancer can be overwhelming, but you don’t have to face it alone. This September, for Leukemia and Lymphoma Awareness Month, connect with Cancer Expert Now to get the expert guidance you need. Our top oncologists are here to provide answers, clarity, and peace of mind so you can move forward with confidence. 💪 Don’t wait—reach out today and let us support you and your loved ones in this journey. Learn more: https://lnkd.in/diBi9Qc #LeukemiaAwareness #LymphomaAwareness #CancerExpertNow #CancerSupport #LeukemiaLymphomaAwarenessMonth

September is Leukemia & Lymphoma Awareness Month. 💙 For those facing these challenges, ongoing follow-up and treatment management is crucial. Knowing the specific type of leukemia or lymphoma helps tailor the best care and predict outcomes. We're here to support you every step of the way! 📞702.380.8300 🔗Link in bio #ProCareHospice #LeukemiaAwareness #LymphomaAwareness #LasVegasHospice #LasVegasCare

Establishing rapport, building trust, and empowering patients with cancer are important outcomes of effective patient-provider communication. Learn more about key insights derived from ACCC and The Leukemia & Lymphoma Society focus groups in the most recent Oncology Issues: https://bit.ly/4ddUy5Q.

Analyze in a different light! Join us in this webinar series on leukemia and lymphoma analysis

🚨 Did you know? Diffuse large b-cell lymphoma, the most common type of non-Hodgkin’s lymphoma in the US, affects 30,000 new patients each year. With a relapse rate of up to 40% within two years, ongoing advancements in treatment are critical. ✨ Good news is on the horizon: #DLBCL is curable in 60-70% of cases with initial therapy. 🤝 In ACCC’s partnership with The Leukemia and Lymphoma Society we have produced https://bit.ly/3WPkJe5, a guide designed to hone communication, clarify treatment expectations, and help boost patient confidence through shared decision-making. 🔗 https://bit.ly/3wMWJgT Access the guide, a communication road map, and resource library to transform DLBCL treatment and patient engagement. Will you be at #ASCO24? Come visit ACCC’s booth, we’ll see you in Chicago! #LymphomaAwareness #HealthCommunication

There was a lot of amazing research presented at ASH this year around the tremendous progress that's been made using OGM for leukemia, lymphoma, and myeloma (https://lnkd.in/eZgTk8aV):

An estimated 1.6 million people in the U.S. are living with or in remission from leukemia, lymphoma, myeloma, myelodysplastic syndromes (MDS) or myeloproliferative neoplasms (MPNs). Join us in supporting The Leukemia & Lymphoma Society on their #BloodCancerAwarenessMonth campaign. #CancelBloodCancer #BelieversintheExtraordinary #BelieversinPatients

In the upcoming 5th edition of the World Health Organization Classification of Haematolymphoid Tumors, CD5-negative B-cell prolymphocytic leukemia has been replaced. The new entity is known as splenic B-cell lymphoma/leukemia with prominent nucleoli. What are your thoughts on this update?

This unique case underscores the challenges in diagnosing and managing ocular manifestations of mantle cell lymphoma, a rare and usually high-grade type of non-Hodgkin lymphoma. https://lnkd.in/eG_JKjeg #Ophthalmology #ClinicalResearch #OcularOncology